DnaG primase—A target for the development of novel antibacterial agents

Stefan Ilic, Shira Cohen, Benjamin Tam, Adi Dayan, Barak Akabayov

Research output: Contribution to journalReview articlepeer-review


The bacterial primase—an essential component in the replisome—is a promising but underexploited target for novel antibiotic drugs. Bacterial primases have a markedly different structure than the human primase. Inhibition of primase activity is expected to selectively halt bacterial DNA replication. Evidence is growing that halting DNA replication has a bacteriocidal effect. Therefore, inhibitors of DNA primase could provide antibiotic agents. Compounds that inhibit bacterial DnaG primase have been developed using different approaches. In this paper, we provide an overview of the current literature on DNA primases as novel drug targets and the methods used to find their inhibitors. Although few inhibitors have been identified, there are still challenges to develop inhibitors that can efficiently halt DNA replication and may be applied in a clinical setting.

Original languageAmerican English
Article number72
Issue number3
StatePublished - 1 Sep 2018


  • Antibacterial agents
  • Antibiotics
  • Bacterial inhibitors
  • DNA replication
  • DnaG primase

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'DnaG primase—A target for the development of novel antibacterial agents'. Together they form a unique fingerprint.

Cite this